Everest Medicines Limited, incorporated in the Cayman Islands and listed under Stock Code 1952, has announced the completion of a placing of existing shares and a top-up subscription of new shares under a general mandate. The company successfully placed an aggregate of 22,561,000 sale shares through placement agents, on a best effort basis, to not less than six placees, at a purchase price of HK$69.70 per sale share. This strategic move is part of the company's efforts to optimize its capital structure and support its ongoing business initiatives. Everest Medicines' Board, led by Chairman and Executive Director Wei Fu, expressed satisfaction with the successful completion of the transaction.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。